You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

~ Buy the APLENZIN (bupropion hydrobromide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR APLENZIN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for APLENZIN

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	Johns Hopkins University	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	National Institute on Drug Abuse (NIDA)	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	SRI International	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	University of Bristol	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗	Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.	Completed	Stanford University	Phase 4	2009-07-01	The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT02129751 ↗	Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder	Not yet recruiting	Bausch Health Americas, Inc.	Phase 4	2021-11-01	Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for APLENZIN

Condition Name

Chart
Table

Condition Name for APLENZIN
Intervention	Trials
Major Depressive Disorder	1
Smoking	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for APLENZIN
Intervention	Trials
Disease	1
Depressive Disorder, Major	1
Depressive Disorder	1
Depression	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for APLENZIN

Trials by Country

Map
Table

Trials by Country for APLENZIN
Location	Trials
United States	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for APLENZIN
Location	Trials
New Jersey	1
Washington	1
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for APLENZIN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for APLENZIN
Clinical Trial Phase	Trials
Phase 4	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for APLENZIN
Clinical Trial Phase	Trials
Not yet recruiting	1
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for APLENZIN

Sponsor Name

Chart
Table

Sponsor Name for APLENZIN
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	1
SRI International	1
University of Bristol	1
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for APLENZIN
Sponsor	Trials
Industry	3
Other	3
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.